Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00859781 · ClinicalTrials.gov registry record · Phase 2
177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer
A Phase 2 study of Prostate Cancer, sponsored by Weill Medical College of Cornell University.
- Active
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
- 9
- Study locations
NCT00859781 is a Phase 2 study of Prostate Cancer that is active but no longer recruiting, run by Weill Medical College of Cornell University. The registered enrollment target is 55 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (91% lower). The trial reports 9 study locations across 8 states.
The verdict
NCT00859781, a Phase 2 study of Prostate Cancer, is active but no longer recruiting, sponsored by Weill Medical College of Cornell University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to test the effectiveness of the experimental drug, 177Lu-J591 in combination with ketoconazole and hydrocortisone against prostate cancer.
Conditions Studied
Interventions
- DRUG Hydrocortisone
- DRUG 177Lu-J591
- DRUG Ketoconazole
- DRUG 111In-J591
Study Locations (9)
California
- Cedars Sinai - Los Angeles
- USC/Norris Comprehensive cancer center - Los Angeles
District of Columbia
- Georgetown University Medical Center - Washington D.C.
Indiana
- Indiana University Melvin and Bren Simon Cancer Center - Indianapolis
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Kansas
- The University of Kansas Cancer Center - Westwood
New York
- Weill Cornell Medical College - New York
Pennsylvania
- UPMC Hillman Cancer Center - Pittsburgh
Utah
- University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2009-06 |
| Est. Completion | 2026-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00859781
The ClinicalTrials.gov registry entry for NCT00859781 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (91% lower). The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 4 interventions - of which Hydrocortisone is the first listed.
NCT00859781 reports 9 study locations spanning 8 distinct geographic areas - top geographies include California, District of Columbia, Indiana.
Frequently Asked Questions
What is clinical trial NCT00859781 about?
NCT00859781 is a clinical study titled "177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer". The purpose of this study is to test the effectiveness of the experimental drug, 177Lu-J591 in combination with ketoconazole and hydrocortisone against prostate cancer.
What is the current status of trial NCT00859781?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2009-06. Estimated completion is 2026-05.
What conditions does trial NCT00859781 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT00859781?
The interventions under investigation include: Hydrocortisone (DRUG), 177Lu-J591 (DRUG), Ketoconazole (DRUG), 111In-J591 (DRUG).
Who is sponsoring clinical trial NCT00859781?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00859781 being conducted?
This trial has 9 study locations across California, District of Columbia, Indiana, Iowa, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.